secwatch / observer
8-K filed June 12, 2023, 7:59 PM ET ticker TOI CIK 0001799191
leadership confidence high sentiment neutral materiality 0.55

Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO

Oncology Institute, Inc.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brad Hively

Vice Chair of the Board
TOI · Oncology Institute, Inc.
Effective
2023-06-30
Filed
June 12, 2023, 7:59 PM ET
Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time
Departed

Brad Hively

Chief Executive Officer
TOI · Oncology Institute, Inc.
Effective
2023-06-30
Successor
Daniel Virnich
Filed
June 12, 2023, 7:59 PM ET
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
Role change

Daniel Virnich

Chief Executive Officer
TOI · Oncology Institute, Inc.
Effective
2023-06-30
Filed
June 12, 2023, 7:59 PM ET
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brad Hively was appointed as Vice Chair of the Board at Oncology Institute, Inc..

Action
appointed
Role
Vice Chair of the Board
Exact text from the filing
Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brad Hively resigned as Chief Executive Officer at Oncology Institute, Inc..

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR
accession 0001799191-23-000012
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.